Report      Database

    Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

    Date: 21 Jun, 2010              Type: Life Science              Pages: 87

    Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1
    • Electronic Access - Single User License
      $1,100.00
    • CD-ROM Mail Delivery
      $1,250.00
    • Hard-copy Mail Delivery
      $1,250.00
    • Electronic Access - Multi User License
      $1,600.00

    Report Details
     
    “Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering:
     
    • Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast 
    • Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
    • Region wise Diabetes Health Expenditure and Mortality 
    • Top 10 Countries Diabetes Population and Future Forecast 
    • Top 5 Countries Diabetes Drug Market and Future Forecast 
    • Top 7 Countries Insulin Market and Future Forecast
    • Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market
    • Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market
    • Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market
    • Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market  
     
    Research Highlights
     
    • USA controls more than 50% of the total Diabetes Drug market share in 2009
    • Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
    • China will have the second highest Insulin market share by 2012 replacing Germany
    • DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
    • GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015
    • Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015. 
    • Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030. 
    • Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more than US$ 4 Billion by 2017
    • Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists 
    • China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
    • Japan Insulin market is expected to be more than US$ 1 Billion by 2010
     
    Key Drugs Analyzed
     
    Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix 
    Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus,  Humalog, Humulin, Apidra, Lantus 
    DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus, 
    GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria,  Taspoglutide
     
    Data Sources 
     
    Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.  

    1. Executive Summary
     
    2. Global Diabetes Market

    2.1 Global – Diabetes Drug Market & Future Forecast
    2.2 Global – Insulin Market & Future Forecast
    2.3 Global – Diabetes Drug Market Share & Future Forecast of (Brazil, China, Japan, USA, India)
    2.4 Global – Insulin Market Share & Future Forecast of (Mexico, Germany, Russia, China, Japan, USA, India) 
    2.5 Global – Dipeptidyl Peptidase (DPP – IV) Inhibitors Market & Future Forecast
    2.6 Global – Glucagon-like Peptide-1(GLP-1) Market & Future Forecast
     
    3. Global – Top 6 Diabetes Drug Brands Market Performance
    3.1 Avandia – Past & Present Market
    3.2 Actos – Past, Present & Future Forecast
    3.3 Amaryl – Past, Present & Future Forecast
    3.4 Avandamet – Past, Present & Future Forecast
    3.5 Prandin/Novonorm – Past & Present Market
    3.6 Starlix – Past, Present & Future Forecast
     
    4. Global – Top 9 Insulin Brands Market Performance
    4.1 Novomix – Past, Present & Future Forecast
    4.2 Novorapid – Past, Present & Future Forecast
    4.3 Levemir – Past, Present & Future Forecast
    4.4 Degludec – Yet to be Launched - Future Forecast
    4.5 Degludecplus – Yet to be Launched – Future Forecast
    4.6 Humalog – Past & Present Market
    4.7 Humulin – Past & Present Market
    4.8 Apidra – Past, Present & Future Forecast
    4.9 Lantus – Past, Present & Future Forecast
     
    5. Global – DPP-IV Inhibitors Brands Market Performance
    5.1 Januvia – Past, Present & Future Forecast
    5.2 Onglyza – Past, Present & Future Forecast
    5.3 Alogliptin – Yet to be Launched – Future Forecast
    5.4 Galvus – Past, Present & Future Forecast
    5.5 DPP-IV Inhibitors – In Trial Phases
     
    6. Global – GLP-1 Agonists Brands Market Performance
    6.1 Byetta – Past, Present & Future Forecast
    6.2 Victoza – Past, Present & Future Forecast
    6.3 Exenatide LAR – Yet to be Launched – Future Forecast
    6.4 Syncria – Yet to be Launched – Future Forecast
    6.5 Taspoglutide – Yet to be Launched – Future Forecast
     
    7. Regional Estimates for Diabetes
    7.1 Diabetes – Population & Prevalence
    7.2 Impaired Glucose Tolerance (IGT) – Population & Prevalence
    7.3 Mortality – Due to Diabetes
    7.4 North America & Caribbean Region
    7.4.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
    7.4.2 Healthcare Expenditure & Type 1 Diabetes
    7.4.3 Mortality
    7.5 Middle East and North African Region
    7.5.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
    7.5.2 Healthcare Expenditure & Type 1 Diabetes
    7.5.3 Mortality
    7.6 South-East Asian Region
    7.6.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
    7.6.2 Healthcare Expenditure & Type 1 Diabetes
    7.6.3 Mortality
    7.7 European Region
    7.7.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
    7.7.2 Healthcare Expenditures & Type 1 Diabetes
    7.7.3 Mortality
    7.8 South and Central American Region
    7.8.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
    7.8.2 Healthcare Expenditures & Type 1 Diabetes
    7.8.3 Mortality
    7.9 Western Pacific Region
    7.9.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
    7.9.2 Healthcare Expenditures & Type 1 Diabetes
    7.9.3 Mortality
    7.10 African Region
    7.10.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence
    7.10.2 Healthcare Expenditure & Type 1 Diabetes
    7.10.3 Mortality
     
    8. Global – Top 10 Diabetic Countries Performance
    8.1 Number of People in Top 10 Diabetic Place
    8.2 Prevalence of Diabetes in Top 10 Countries
    8.3 India
    8.3.1 Diabetes Population & Future Scenario
    8.3.2 India – Diabetes Drug Market & Future Forecast
    8.3.3 India-Insulin Market & Future Forecast
    8.4 China
    8.4.1 Diabetes Population & Future Scenario
    8.4.2 Diabetes Drug Market & Future Forecast
    8.4.3 China Insulin Market & Future Forecast
    8.5 United States
    8.5.1 Diabetes Population & Future Scenario
    8.5.2 Diabetes Drug Market & Future Forecast
    8.5.3 Insulin Market & Future Forecast
    8.6 Brazil
    8.6.1 Diabetes Population & Future Scenario
    8.6.2 Diabetes Drug Market & Future Forecast
    8.7 Russia
    8.7.1 Diabetes Population & Future Scenario
    8.7.2 Insulin Market & Future Forecast
    8.8 Japan
    8.8.1 Diabetes Population & Future Scenario
    8.8.2 Diabetes Drug Market & Future Forecast
    8.8.3 Insulin Market & Future Forecast
    8.9 Germany
    8.9.1 Diabetes Population & Future Scenario
    8.9.2 Insulin Market & Future Forecast
    8.10 Mexico
    8.10.1 Diabetes Population & Future Scenario
    8.10.2 Insulin Market & Future Forecast
    8.11 Indonesia
    8.11.1 Diabetes Population & Future Scenario
    8.12 Pakistan
    8.12.1 Diabetes Population & Future Scenario

    List of Figures:
     
    Figure 2 1: Global – Diabetes Drug Market (Billion US$), 2005 – 2009
    Figure 2 2: Global – Forecast of Diabetes Drug Market (Billion US$), 2010 – 2013
    Figure 2 3: Global – Insulin Market (Billion US$), 2004 – 2009
    Figure 2 4: Global – Forecast of Insulin Market (Billion US$), 2010 – 2013
    Figure 2 5: Global – Diabetes Drug Market Share of (Brazil, China, Japan, USA, India) (Percent), 2007 – 2009
    Figure 2 6: Global – Forecast of Diabetes Drug Market Share of (Brazil, China, Japan, USA, India) (Percent), 2010 – 2013
    Figure 2 7: Global – Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA, India) (Percent), 2007 – 2009
    Figure 2 8: Global – Forecast for Insulin Market Share of (Mexico, Germany, Russia, China, Japan, USA, India) (Percent), 2010 – 2013
    Figure 2 9: Global – DPP – IV Inhibitors Market (Million US$), 2009 – 2015
    Figure 2 10: Global – GLP-1 Market (Million US$), 2009 – 2015
    Figure 3 1: Global – Avandia Diabetes Drug Brand Sales (Million US$), 2004 – 2009
    Figure 3 2: Global – Actos Diabetes Drug Sales (Billion US$), 2005 – 2009
    Figure 3 3: Global – Forecast for Actos Diabetes Drug Sales (Billion US$), 2010 & 2013
    Figure 3 4: Global – Amaryl Diabetes Drug Sales (Million US$), 2006, 2007, 2009, & Q1 2010
    Figure 3 5: Global – Forecast for Amaryl Diabetes Drug Sales (Million US$), 2010 – 2012
    Figure 3 6: Global – Avandamet Diabetes Drug Sales (Million US$), 2006 – 2009
    Figure 3 7: Global – Forecast for Avandamet Diabetes Drug Sales (Million US$), 2010 – 2012
    Figure 3 8: Global – Prandin/Novonorm Diabetes Drug Sales (Million US$), 2007 – 2009
    Figure 3 9: Global – Starlix Diabetes Drug Sales (Million US$), 2007 – 2009E
    Figure 3 10: Global – Forecast for Starlix Diabetes Drug Sales (Million US$), 2010 – 2012
    Figure 4 1: Global – NovoMix Insulin Sales (Million US$), 2005 – 2009
    Figure 4 2: Global – NovoRapid Insulin Sales (Million US$), 2005 – 2009
    Figure 4 3: Global – Levemir Insulin Sales (Million US$), 2005 – 2009
    Figure 4 4: Global – Humalog Insulin Sales (Million US$), 2006 – 2009
    Figure 4 5: Global – Humulin Insulin Brand Sales (Million US$), 2006 – 2009
    Figure 4 6: Global – Apidra Insulin Sales (Million US$), 2005 – 2009, Q1 2010
    Figure 4 7: Apidra – Forecast for Insulin Sales (Million US$), 2009 – 2013
    Figure 4 8: Global – Lantus Insulin Sales (Million US$), 2006 – 2009, Q1 2010
    Figure 4 9: Global – Forecast for Lantus Insulin Sales (Million US$), 2010 – 2015
    Figure 5 1: Global – Januvia DPP-IV Inhibitors Sales (Million US$), 2007 – 2009
    Figure 5 2: Global – Forecast for Januvia DPP-IV Inhibitors Sales (Million US$), 2010 – 2017
    Figure 5 3: Global – Onglyza DPP-IV Inhibitors Sales & Future Forecast (Million US$), 2009 – 2017
    Figure 5 4: Global – Future Forecast for Alogliptin DPP-IV Inhibitors Sale (Million US$), 2011 – 2017
    Figure 5 5: Global – Galvus DPP-IV Inhibitors Sale (Million US$), 2007 – 2009 
    Figure 5 6: Global – Future Forecast for Galvus DPP-IV Inhibitors Sale (Million US$), 2010 – 2012
    Figure 6 1: Global – Byetta GLP-1 Sales (Million US$), 2006 – 2009
    Figure 6 2: Global – Forecast for Byetta GLP-1 Sales (Million US$), 2010 – 2017
    Figure 6 3: Global – Victoza GLP-1 Sales & Future Forecast (Million US$), 2009 – 2017
    Figure 6 4: Global – Forecast for Exenatide LAR GLP-1 Sales (Million US$), 2011 – 2017
    Figure 6 5: Global – Forecast for Syncria GLP-1 Sales (Million US$), 2013 – 2017
    Figure 6 6: Global – Forecast for Taspoglutide GLP-1 Sales (Million US$), 2012 – 2017
    Figure 8 1: India – Number of People with Diabetes (Million), 2003, 2007, 2010
    Figure 8 2: India – Diabetes Drug Market (Billion INR), 2006 – 2009
    Figure 8 3: India – Forecast for Diabetes Drug Market (Billion INR), 2010 – 2014
    Figure 8 4: India – Share of Human Insulin Market, Animal Insulin Market & Oral Diabetes Market (in Percent), 2003 & 2007
    Figure 8 5: India – Insulin Market (Million INR), 2006 – 2009
    Figure 8 6: India – Forecast for Insulin Market (Million INR), 2010 – 2014
    Figure 8 7: China – Number of Diabetes Patients (Million), 2003, 2007 & 2010
    Figure 8 8: China – Diabetes Drug Market (Billion Yuan), 2006 – 2009E
    Figure 8 9: China – Forecast for Diabetes Drug Market (Billion Yuan) 2010 – 2014
    Figure 8 10: China – Insulin Market (Million Yuan), 2007 – 2009
    Figure 8 11: China – Forecast for Insulin Market (Million Yuan), 2010 – 2014
    Figure 8 12: USA – Number of Diabetes Patients (Million), 2003, 2006, 2007 & 2010
    Figure 8 13: USA – Diabetes Drug Market (Million US$), 2002 – 2009
    Figure 8 14: USA – Forecast for Diabetes Drug Market (Million US$), 2010 – 2014
    Figure 8 15: USA – Insulin Market (Billion US$), 2003 – 2009
    Figure 8 16: USA – Forecast for Insulin Market (Billion US$), 2010 – 2014
    Figure 8 17: Brazil – Diabetes Population (Million), 2003, 2007 & 2010
    Figure 8 18: Brazil – Diabetes Drug Market (Million US$), 2008 – 2013
    Figure 8 19: Russia – Number of Diabetes Population (Million), 2005 & 2010
    Figure 8 20: Russia – Insulin Market (Million US$), 2002, 2005 – 2009
    Figure 8 21: Russia – Forecast for Insulin Market (Million US$), 2010 – 2014
    Figure 8 22: Japan – Number of Diabetes Population (Million), 2003 – 2010
    Figure 8 23: Japan – Diabetes Drug Market (Million US$), 2002 – 2009
    Figure 8 24: Japan – Forecast for Diabetes Market (Million US$), 2010 – 2014
    Figure 8 25: Japan – Insulin Market (Million US$), 1998 – 2009
    Figure 8 26: Japan – Forecast for Insulin Market (Million US$), 2010 – 2014
    Figure 8 27: Germany – Number of Diabetes Patients (Million), 2003 – 2010
    Figure 8 28: Germany – Insulin Market (Million US$), 2004 – 2009E
    Figure 8 29: Germany – Forecast for Insulin Market (Billion US$), 2010 – 2014
    Figure 8 30: Mexico – Number of People with Diabetes (Million), 2003 – 2005, 2007 & 2010
    Figure 8 31: Mexico – Insulin Market (Million US$), 2004 – 2009E
    Figure 8 32: Mexico – Forecast for Insulin Market (Million US$), 2010 – 2014
    Figure 8 33: Pakistan – Number of Diabetes Patients (Million), 2003, 2007 & 2010

     
    List of Tables:
     
    Table 4 1: Novomix – Forecast for Insulin Sales (Million US$), 2010 – 2030
    Table 4 2: Global – Forecast for NovoRapid Insulin Sales (Million US$), 2010 – 2030
    Table 4 3: Global – Forecast for Levemir Insulin Sales (Million US$), 2010 – 2030
    Table 4 4: Degludec – Forecast for Insulin Sales (Million US$), 2010 – 2030
    Table 4 5: DegludecPlus – Forecast for Insulin Sales (Million US$), 2010 – 2030
    Table 5 1: DPP-4 Inhibitors –In Trial Phase
    Table 7 1: Regional – Estimates for (Number of People with Diabetes, Comparative Diabetes Prevalence %) (20-79 years), 2010 and 2030
    Table 7 2: Regional – Estimates for (Number of People with IGT, Comparative IGT Prevalence %) (20-79 years), 2010 and 2030
    Table 7 3: Regional – Diabetes Mortality (20-79 Years; Thousand), 2010
    Table 7 4: North America and Caribbean Region – Population & Adult Population (Million), 2010 & 2030
    Table 7 5: North America and Caribbean Region – Number of People with Diabetes & Comparative Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030
    Table 7 6: North America and Caribbean Region – Number of People with IGT & Comparative Prevalence Percent (20-79 Years; Million, Percent), 2010 & 2030
    Table 7 7: North America and Caribbean Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    Table 7 8: North America and Caribbean Region – Diabetes Mortality (20-79 Years; Thousand), 2010
    Table 7 9: Middle East and North African Region – Population & Adult Population (Million), 2010 & 2030
    Table 7 10: Middle East and North African Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    Table 7 11: Middle East and North African Region – Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    Table 7 12: Middle East and North African Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    Table 7 13: Middle East and North African Region – Diabetes Mortality (20-79 Years; Thousand), 2010
    Table 7 14: South-East Asian Region – Population & Adult Population (Million), 2010 & 2030
    Table 7 15: South-East Asian Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    Table 7 16: South-East Asian Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    Table 7 17: South-East Asian Region – Diabetes Mortality (20-79 Years; Thousand), 2010
    Table 7 18: European Region – Population & Adult Population (Million), 2010 & 2030
    Table 7 19: European Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million Percent), 2010 & 2030
    Table 7 20: European Region – Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    Table 7 21: European Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    Table 7 22: European Region – Diabetes Mortality (20-79 Years; Thousand), 2010
    Table 7 23: South and Central American Region – Population & Adult Population (Million), 2010 & 2030
    Table 7 24: South and Central American Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    Table 7 25: South and Central American Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    Table 7 26: South and Central American Region – Diabetes Mortality (20-79 Years; Thousand), 2010
    Table 7 27: Western Pacific Region – Population & Adult Population (Million), 2010 & 2030
    Table 7 28: Western Pacific Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    Table 7 29: Western Pacific Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    Table 7 30: Western Pacific Region – Diabetes Mortality (20-79 Years; Thousand), 2010
    Table 7 31: African Region – Population & Adult Population (Million), 2010 & 2030
    Table 7 32: African Region – Number of People with Diabetes & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    Table 7 33: African Region – Number of People with IGT & Comparative Prevalence (20-79 Years; Million, Percent), 2010 & 2030
    Table 7 34: African Region – Health Expenditure for Diabetes (Billion) & Type 1 Diabetes (0-14 Years; Thousand), 2010 & 2030
    Table 7 35: African Region – Diabetes Mortality (20-79 Years; Thousand), 2010
    Table 8 1: Global – Top 10 Countries Number of People with Diabetes (20-79 age group) (Million) 2010 & 2030
    Table 8 2: Global – Top 10 Countries in Prevalence of Diabetes (20-79 age group) (Percent), 2010 & 2030
    Table 8 3: India – Forecast for Number of People with Diabetes (Million), 2011 – 2030
    Table 8 4: China – Forecast for Number of Diabetes Patients (Million), 2011 – 2030
    Table 8 5: USA – Forecast for Number of Diabetes Patients (Million), 2011 – 2030
    Table 8 6: Brazil – Forecast for Number of Diabetes Population (Million), 2011 – 2030
    Table 8 7: Russia – Forecast for Number of Diabetes Population (Million), 2011 – 2030
    Table 8 8: Mexico – Forecast for Number of Diabetes Patients (Million), 2011 – 2030
    Table 8 9: Indonesia – Forecast for Number of Diabetes Patients (Million), 2010 – 2030
    Table 8 10: Pakistan – Forecast for Number of Diabetes Patients (Million), 2011 – 2030


    Related Products